Washington Advances Medical Cannabis Documentation Process for Rescheduling

Washington builds a documentation pathway

Washington regulators are creating a way for marijuana businesses to prove they take part in the state's medical cannabis market.

According to Marijuana Moment, the effort is meant to ease access to benefits that come with the Trump administration's partial rescheduling move. The process would let a business document its medical participation. It isn't described as a finished rule.

The published summary doesn't specify the vehicle, the timeline, or the form operators would file. Those details will decide whether this is a paperwork exercise or a real compliance gate.

The April order draws its line at medical

Attorney General Todd Blanche's April order created a partial rescheduling, and the benefits appear to track medical-market status.

Marijuana Moment reported that the order, issued by Blanche in April, addresses marijuana products regulated under state law. The excerpt available to us cuts off mid-sentence while describing which products are covered. Its framing is still clear: the federal relief is keyed to the medical market, and Washington is responding by building a way to show who belongs in it.

That's a notable design choice. Relief that attaches to a category of state licensee, rather than to the plant itself, puts the burden of proof on the operator. Someone has to certify the category. Washington has decided it will be the state.

On a strict reading, 280E turns on schedule, not business model

Section 280E of the Internal Revenue Code denies deductions based on a substance's federal schedule, which is why documentation now carries tax weight.

On a strict reading, IRC §280E bars deductions and credits for any trade or business that consists of trafficking in a controlled substance listed in Schedule I or II of the Controlled Substances Act. The statute asks one question: where does the substance sit on the federal schedules? It doesn't ask whether the product was sold for medical or adult use.

So the tax result depends entirely on how the April order treats medical marijuana. To the extent the order moves state-regulated medical product outside Schedule I, a business selling it could stand on different footing than one selling product the order leaves in place. The same license could now produce two tax categories.

The statute never asks whether a business is medical. The April order does, and Washington's paperwork is meant to bridge that gap.

Why the proof problem lands on operators

A business that can't document medical participation may not be able to claim whatever relief the order provides.

This is a taxonomy problem. A licensee's revenue can be split across medical and non-medical sales, and each bucket could sit on a different side of 280E. Any return that claims deductions on the favorable bucket will need records behind it. A state-issued document is the cleanest evidence available.

Washington's move isn't a surprise. State regulators already hold the license files, and they are the only party positioned to certify participation in a state-run medical market at scale. Federal agencies can't easily replicate that.

Operators with mixed revenue should treat the bookkeeping as the real work. Segregating medical and non-medical sales, product by product and register by register, is far cheaper to do before an audit than during one. (Tax advisers will have their own view on timing, but the direction is hard to argue with.)

What remains unpublished

The rule text, the effective date, and any IRS treatment of state-issued documentation aren't yet public in the material available.

Marijuana Moment's summary doesn't give those details. Nothing in the signal indicates the IRS has said how it would treat a state-issued medical-participation record, or whether it would accept one at all. Washington can build the pathway. Only federal authorities can say what it's worth on a return.

Other states with medical programs, including California and Ohio, face the same question about how their licensees will prove eligibility. Whether they copy Washington's approach is open. A patchwork of state documentation regimes would add compliance cost for multistate operators, which is the opposite of what rescheduling was supposed to deliver.

For full background on this story, see the CannIntel topic hub on DEA rescheduling. The DEA's role in the broader process remains separate from the tax questions raised here.

The next signal: the text of Washington's process and any IRS word on whether it will accept it. Until both exist, the paperwork may matter as much as the product.